title: Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response.
abstract: Measurement of Wisteria floribunda agglutinin-positive human Mac-2 binding protein (WFA+-M2BP) in serum was recently shown to be a noninvasive method to assess liver fibrosis. The aim of this study was to evaluate the utility of serum WFA+-M2BP values to predict the development of hepatocellular carcinoma (HCC) in patients who achieved a sustained virological response (SVR) by interferon treatment. For this purpose, we retrospectively analyzed 238 patients with SVR who were treated with interferon in our department. Serum WFA+-M2BP values were measured at pre-treatment (pre-Tx), post-treatment (24 weeks after completion of interferon; post-Tx), the time of HCC diagnosis, and the last clinical visit. Of 238 patients with SVR, HCC developed in 16 (6.8%) patients. The average follow-up period was 9.1 years. The cumulative incidence of HCC was 3.4% at 5 years and 7.5% at 10 years. The median pre-Tx and post-Tx WFA+-M2BP values were 1.69 (range: 0.28 to 12.04 cutoff index (COI)) and 0.80 (range: 0.17 to 5.29 COI), respectively. The WFA+-M2BP values decreased significantly after SVR (P < 0.001). The median post-Tx WFA+-M2BP value in patients who developed HCC was significantly higher than that in patients who did not (P < 0.01). Multivariate analysis disclosed that age (> 60 years), sex (male), pre-Tx platelet count (< 15.0×10(3)/μL), and post-Tx WFA+-M2BP (> 2.0 COI) were associated with the development of HCC after SVR. Conclusion: Post-Tx WFA+-M2BP (> 2.0 COI) is associated with the risk for development of HCC among patients with SVR. The WFA+-M2BP values could be a new predictor for HCC after SVR.
authors.affiliation: Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.
authors.forename: Ryu
authors.initials: R
authors.lastname: Sasaki
authors.affiliation: Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.
authors.forename: Kazumi
authors.initials: K
authors.lastname: Yamasaki
authors.affiliation: Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.
authors.forename: Seigo
authors.initials: S
authors.lastname: Abiru
authors.affiliation: Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.
authors.forename: Atsumasa
authors.initials: A
authors.lastname: Komori
authors.affiliation: Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.
authors.forename: Shinya
authors.initials: S
authors.lastname: Nagaoka
authors.affiliation: Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Saeki
authors.affiliation: Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.
authors.forename: Satoru
authors.initials: S
authors.lastname: Hashimoto
authors.affiliation: Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.
authors.forename: Shigemune
authors.initials: S
authors.lastname: Bekki
authors.affiliation: Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Kugiyama
authors.affiliation: Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kuno
authors.affiliation: The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Korenaga
authors.affiliation: Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Togayachi
authors.affiliation: Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Ocho
authors.affiliation: The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Mizokami
authors.affiliation: Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan.
authors.forename: Hisashi
authors.initials: H
authors.lastname: Narimatsu
authors.affiliation: Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
authors.forename: Tatsuki
authors.initials: T
authors.lastname: Ichikawa
authors.affiliation: Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Nakao
authors.affiliation: Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yatsuhashi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D000998:Antiviral Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D001706:Biopsy; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D006801:Humans; D015994:Incidence; D008113:Liver Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D037121:Plant Lectins / Q000097:blood*; D011379:Prognosis; D034781:Receptors, N-Acetylglucosamine / Q000097:blood*; D012307:Risk Factors; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult
chemical_list: D000951:Antigens, Neoplasm; D000998:Antiviral Agents; D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; D037121:Plant Lectins; D034781:Receptors, N-Acetylglucosamine; C114782:TAA90K protein, human; C040129:wisteria lectin